Invest in Infinite Potential

We are changing the paradigm of life sciences and the way we develop diagnostics, therapeutics and reproductive medicine

micro.png

NovelStem International Corp. focuses on the development and commercialization of diagnostic technology that can predict patients’  anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy

NovelStem was formerly known as Hollywood Media Corp. We changed our name to NovelStem International Corp. in September 2018 as a result of our business focus shift from a media business to stem cell-based diagnostics for cancer chemotherapies. NovelStem owns a legacy business interest, 50% interest in Netco Partners, which in turn owns "Net Force," a publishing book franchise.

NovelStem International Corp.

NS_logo_fin-4.png

NewStem

With its in-depth understanding of human stem cells and its proprietary technology of haploid human embryonic stem cells, NewStem intends to change the paradigm of life sciences and the way we develop diagnostics, therapeutics and reproductive medicine. NovelStem currently owns a 33% interest in NewStem.

Netco Partners

NovelStem owns a 50% interest in Netco Partners, a joint venture that owns the Net Force publishing franchise. Netco Partners has had success with the Net Force book series. Netco is relaunching Net Force, with the release of the first new book in 2019 under an agreement from HarperCollins.

Netforce_newbooks.png

News

Keep me updated on the latest happenings.

Add me to the NovelStem distribution list.

Thanks for subscribing. We will add you to the NSTM distribution list. 

Something went wrong. Please try again later, or email us directly to be put on the list.